DrugPatentWatch Database Preview

Details for Patent: 8,865,698

« Back to Dashboard

Which drugs does patent 8,865,698 protect, and when does it expire?

Patent 8,865,698 protects VITRAKVI and is included in two NDAs.

This patent has ninety-five patent family members in thirty-five countries.

Summary for Patent: 8,865,698

Title:	Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Abstract:	Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: ##STR00001## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, X, Y and n have the meanings given in the specification.
Inventor(s):	Haas; Julia (Boulder, CO), Andrews; Steven W. (Boulder, CO), Jiang; Yutong (Boulder, CO), Zhang; Gan (Niwot, CO)
Assignee:	Array BioPharma Inc. (Boulder, CO)
Application Number:	13/943,590
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,865,698

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes

International Family Members for US Patent 8,865,698

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	074052
Argentina	112833
Australia	2009308465
Australia	2015200511
Australia	2017268517